ANAB AnaptysBio, Inc

NASDAQ
$57.74

AnaptysBio, Inc (ANAB) is expected to report earnings on August 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.22 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.3% since its last earnings release on May 12, 2026.

AnaptysBio Missed Consensus Estimates
Tuesday, May 12, 2026 · 4:15 PM ET
Earnings Date
2nd Quarter, Jun 2026
Aug 5
Wednesday · 4:15 PM ET
Earnings Whisper
-
vs ($0.22)
Rev est $27.4M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $58.01

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About AnaptysBio, Inc

AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow